Mariya Morar
About Mariya Morar
Mariya Morar is a Director of Biophysics at Arcus Biosciences, specializing in target-based inhibitor screening to combat antibiotic resistance. She has extensive experience in research and development, having held positions at various institutions including Gilead Sciences and SABIC.
Current Role at Arcus Biosciences
Mariya Morar currently serves as the Director of Biophysics at Arcus Biosciences. She has held this position since 2023, contributing her expertise in biophysics to advance the company's research initiatives. Her role involves overseeing projects related to structural biology and enzyme characterization, which are critical for the development of new therapeutic strategies.
Previous Experience at Arcus Biosciences
Prior to her current role, Mariya Morar worked at Arcus Biosciences as a Research Fellow in Structural Biology from 2021 to 2023. During this time, she focused on various research projects that leveraged her background in biophysics and structural biology, contributing to the company's understanding of biological systems and potential drug targets.
Professional Background
Mariya Morar has a diverse professional background in the field of biophysics and structural biology. She has held positions at several prestigious institutions, including Gilead Sciences, Baylor College of Medicine, and the University of Toronto. Her experience spans research scientist roles and postdoctoral positions, where she has developed significant expertise in enzyme characterization and antibiotic resistance.
Education and Expertise
Mariya Morar earned a Bachelor of Science (B.S.) in Chemistry from the University of West Florida. She furthered her education at Cornell University, obtaining a Doctor of Philosophy (Ph.D.) in Chemistry and Chemical Biology. Her academic training includes core competencies in the structure-function characterization of enzymes, particularly those involved in antibiotic resistance.
Research Contributions and Projects
Throughout her career, Mariya Morar has made notable contributions to enzyme characterization and engineering. At SABIC KAUST, she developed a platform focused on sustainable chemical production from biosources. Her research also includes specialization in target-based inhibitor screening aimed at reversing antibiotic resistance, addressing critical challenges in the field of biophysics and drug development.